Nanjing Aorui Pharmaceutical develops PROTAC-based small-molecule drugs and has engineered a tumor tissue‑specific E3 ligase for use in PROTAC technology. The company is located in the Nanjing Jiangbei New Area Life and Health Industry Park. It positions PROTAC as a disruptive approach to address previously “undruggable” targets and reports having laid a solid foundation for its PROTAC product development. Nanjing Aorui plans to focus its pipeline on these undruggable targets and accelerate clinical‑demanded innovative drug development. The company is recruiting industry talent to support its R&D efforts. Financially, it completed a near‑RMB 100 million Pre‑A equity financing earlier this year.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

May 2020